Almirall rises after Q1 beats expectations

Almirall

12/05/2025 09:15

** Shares in Spain's Almirall ALM.MC rise over 8% after the pharmaceutical company reported better-than-expected Q1 results

** Jefferies highlights Q1 sales and EBITDA, which came in 1% and 3% above consensus, respectively, as well as net income beat despite higher tax

** It says key growth drivers Ilumetri and Wynzora for plaque psoriasis, and Ebglyss for eczema treatment exceeded broker's projections despite increasing competition and quarterly phasing impacts in the psoriasis market

** It also adds that physician feedback supports fast uptake of Ebglyss in Europe, while further uptake of Ilumetri may be slowed due to competitive market

** If gains hold, the stock will see its best day since February 2022

 (Reporting by Marta Serafinko in Gdansk)

 ((Marta.Serafinko@thomsonreuters.com; +48 58 769 66 00;))